+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Testosterone Replacement Therapy Market 2019-2023 - Product Image

Global Testosterone Replacement Therapy Market 2019-2023

  • ID: 4720651
  • Report
  • Region: Global
  • 102 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Endo Pharmaceuticals
  • MORE
About this market

Increased awareness about hypogonadism among the public and primary care physicians will drive the market. Globally, different organizations are working on initiatives to increase patient awareness of hypogonadism and available treatment options. The vendors are actively taking part in the awareness campaign to educate the population about the diagnoses and treatment for hypogonadism. Also, organizations are increase awareness about hypogonadism among medical professionals. They release clinical practice guidelines on testosterone therapy. The testosterone replacement therapy market growth at a CAGR of more than (2%) during the forecast period.

Market Overview

High prevalence of testosterone deficiency

High prevalence of hypogonadism is related to the social stigma associated with hypogonadism among young men. Hence, demographic tends toward the increasing geriatric population and improved life expectancy result in the increased risk for incidence and prevalence for hypogonadism.

Adverse effects of testosterone replacement therapy

Testosterone replacement therapy is being approved by the FDA and is indicated to treat disorders associated with low levels of testosterone. Therefore, the adverse effects associated with testosterone replacement therapies can decrease [patient compliances, thereby leading to a decline in the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the testosterone replacement therapy market during the 2019-2023, view the report.

Competitive Landscape

The global testosterone replacement therapy market is extremely concentrated since the market has a few vendors that offer limited products with presence of few global and local vendors. The market has witnessed a rise in novel therapeutics approaches which have a positive impact on the market growth. The vendors are increasingly competing against each other based on factors such as innovation, price, operational cost, and product quality. To maintain their market positions, the vendors in this testosterone replacement therapy are focusing on adopting various strategies and this will in turn, help them to strengthen and restructure their activities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Endo Pharmaceuticals
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market segmentation analysis
  • Market characteristics
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Injections - Market size and forecast 2018-2023
  • Topicals - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Market trends
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Bayer
  • Endo Pharmaceuticals
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global endocrinology drugs market
Exhibit 03: Segments of global endocrinology drugs market
Exhibit 04: Market segments
Exhibit 05: Market characteristics
Exhibit 06: Late-stage pipeline analysis drugs for testosterone deficiency
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Injections - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Injections - Year-over-year growth 2019-2023 (%)
Exhibit 23: Topicals - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Topicals - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: AbbVie - Vendor overview
Exhibit 47: AbbVie - Business segments
Exhibit 48: AbbVie - Organizational developments
Exhibit 49: AbbVie - Geographic focus
Exhibit 50: AbbVie - Key offerings
Exhibit 51: Bayer - Vendor overview
Exhibit 52: Bayer - Business segments
Exhibit 53: Bayer - Organizational developments
Exhibit 54: Bayer - Geographic focus
Exhibit 55: Bayer - Segment focus
Exhibit 56: Bayer - Key offerings
Exhibit 57: Endo Pharmaceuticals - Vendor overview
Exhibit 58: Endo Pharmaceuticals - Business segments
Exhibit 59: Endo Pharmaceuticals - Organizational developments
Exhibit 60: Endo Pharmaceuticals - Geographic focus
Exhibit 61: Endo Pharmaceuticals - Segment focus
Exhibit 62: Endo Pharmaceuticals - Key offerings
Exhibit 63: Validation techniques employed for market sizing
Exhibit 64: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Endo Pharmaceuticals
  • MORE
Global Testosterone Replacement Therapy Market 2019-2023

The author of the report recognizes the following companies as the key players in the global testosterone replacement therapy market: AbbVie, Bayer, Endo Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is due to availability of such patient assistance programs, individuals are inclined toward buying these drugs, thereby increasing the growth of the market.”

According to the report, one of the major drivers for this market is the increasing awareness about hypogonadism among the public and primary care physicians will drive the market.

Further, the report states that one of the major factors hindering the growth of this market is the availability of generics in the market acts as a challenge of the growth of the market

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie
  • Bayer
  • Endo Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll